6 August 2015, Ann Arbor, Michigan, USA
Study expands utility of Carmeseal-MD™ (P-188 NF) to both leading causes of death in boys and young men with Duchenne muscular dystrophy (DMD) and provides a path for clinical development in non-ambulatory patients.
Video courtesy of Coalition Duchenne
Phrixus Pharmaceuticals announces the results from a preclinical study published in PLOS ONE that examines the effects of Poloxamer-188 NF (P-188 NF), trademarked as Carmeseal-MD™, on respiratory and cardiac dysfunction in mdx and mdx/utrophin double knock-out mice. Robust effects were observed after dosing mice once-a-day subcutaneously, a novel route of administration for this compound and at a dose level (1 mg/Kg) that is significantly lower than in previously published work.
This study provides the first evidence that P-188 NF protects dystrophic diaphragm muscle in vivo and opens up the possibility of pursuing regulatory approval for P-188 NF using already established respiratory endpoints for clinical development. It also enables a development path in non-ambulatory boys and young men with DMD who cannot participate in current clinical studies, which rely on ambulatory endpoints such as the six minute walk test.
Phrixus is currently preparing for a first trial of P-188 NF in patients with DMD with support from the NIH National Heart, Lung, and Blood Institute (NHLBI) in the United States.
Carmeseal-MD is already available in Europe as part of Phrixus’s European Access Program through Phrixus’s European distributor Ethicor Pharma Ltd.
For more information on Carmeseal-MD (P-188 NF), please visit
For more information on the European Access Program for Carmeseal-MD, please visit